[{"orgOrder":0,"company":"Family Planning Association New South Wales","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Family Planning Association New South Wales","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Family Planning Association New South Wales \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Family Planning Association New South Wales \/ Merck & Co"},{"orgOrder":0,"company":"Bio-innova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"THAILAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bio-innova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bio-innova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-innova \/ Undisclosed"},{"orgOrder":0,"company":"VL-Medi Oy","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FINLAND","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Hematology","graph2":"Phase IV","graph3":"VL-Medi Oy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Implant","sponsorNew":"VL-Medi Oy \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"VL-Medi Oy \/ Merck & Co"},{"orgOrder":0,"company":"Centre Hospitalier Intercommunal Creteil","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Centre Hospitalier Intercommunal Creteil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Intercommunal Creteil \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Centre Hospitalier Intercommunal Creteil \/ Merck & Co"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Organon"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Andromaco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHILE","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Andromaco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andromaco \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Andromaco \/ Undisclosed"},{"orgOrder":0,"company":"NextFertility","sponsor":"SINAE SL","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Desogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"NextFertility","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextFertility \/ SINAE SL","highestDevelopmentStatusID":"1","companyTruncated":"NextFertility \/ SINAE SL"}]

Find Clinical Drug Pipeline Developments & Deals for Cerazette

Cerazette
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Cerazette

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

25 API Suppliers, 8 USDMF, 7 CEP/COS, 4 JDMF, 5 EU WC, 4 NDC API, 15 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

169 FDF Dossiers, 34 FDA Orange Book, 105 Europe, 16 Canada, 4 South Africa, 10 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL-21 - 0.15MG;0.03MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-28 - 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG

DIGITAL CONTENT

10 News #PharmaBuzz

10 News #PharmaBuzz

GLOBAL SALES INFORMATION

14 US Medicaid Prescriptions, 24 Regulatory FDF Prices, 6 Annual Reports

MARKET PLACE

5 APIs, 1 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 7 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

NextFertility

Country

OTS 2025

Not Confirmed

02

Bio-innova

Thailand

OTS 2025

Not Confirmed

03

Bayer AG

Germany

OTS 2025

Not Confirmed

04

Andromaco

Chile

OTS 2025

Not Confirmed

05

Centre Hospitalier Intercommunal Creteil

Country

OTS 2025

Not Confirmed

06

VL-Medi Oy

Country

OTS 2025

Not Confirmed

07

Teva Pharmaceutical Industries

Israel

OTS 2025

Not Confirmed

08

Family Planning Association New South Wales

Country

OTS 2025

Not Confirmed

09

Teva Pharmaceutical Industries

Israel

OTS 2025

Not Confirmed